NASDAQ:POAIPrecision Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Precision Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.67 +0.11 (+7.05 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$1.56Now: $1.67▼$1.7950-Day Range$1.44MA: $1.64▼$1.9952-Week Range$1.25Now: $1.67▼$6.80Volume2.29 million shsAverage Volume1.12 million shsMarket Capitalization$24.22 millionP/E RatioN/ADividend YieldN/ABeta1.62 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Precision Therapeutics. Previous Next 2.4 Community Rank Outperform VotesPrecision Therapeutics has received 138 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPrecision Therapeutics has received 153 “underperform” votes. (Add your “underperform” vote.)Community SentimentPrecision Therapeutics has received 52.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Precision Therapeutics and other stocks. Vote “Outperform” if you believe POAI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe POAI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPrecision Therapeutics does not currently pay a dividend.Dividend GrowthPrecision Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precision Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.76% of the stock of Precision Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 2.88% of the stock of Precision Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:POAI Previous Symbol CUSIPN/A CIK1446159 Webwww.precisiontherapeutics.com Phone651-389-4800Debt Debt-to-Equity Ratio0.22 Current Ratio0.30 Quick Ratio0.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.41 million Price / Sales17.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book0.61Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-19,390,000.00 Net Margins-1,420.59% Return on Equity-73.02% Return on Assets-42.19%Miscellaneous Employees24 Outstanding Shares14,500,000Market Cap$24.22 million Next Earnings Date8/17/2020 (Estimated) OptionableNot Optionable $1.67 +0.11 (+7.05 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive POAI News and Ratings via Email Sign-up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter. Precision Therapeutics (NASDAQ:POAI) Frequently Asked Questions How has Precision Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Precision Therapeutics' stock was trading at $2.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, POAI shares have decreased by 22.0% and is now trading at $1.67. View which stocks have been most impacted by Coronavirus. When is Precision Therapeutics' next earnings date? Precision Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020. View our earnings forecast for Precision Therapeutics. How were Precision Therapeutics' earnings last quarter? Precision Therapeutics Inc (NASDAQ:POAI) released its earnings results on Monday, June, 8th. The medical instruments supplier reported ($0.93) earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $0.30 million for the quarter. Precision Therapeutics had a negative net margin of 1,420.59% and a negative return on equity of 73.02%. View Precision Therapeutics' earnings history. Has Precision Therapeutics been receiving favorable news coverage? Media stories about POAI stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Precision Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days. View the latest news about Precision Therapeutics. Are investors shorting Precision Therapeutics? Precision Therapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 172,900 shares, a decline of 7.4% from the June 30th total of 186,800 shares. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is presently 0.2 days. Currently, 1.6% of the company's stock are short sold. View Precision Therapeutics' Current Options Chain. Who are some of Precision Therapeutics' key competitors? Some companies that are related to Precision Therapeutics include ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), Allied Healthcare Products (AHPI), Ocugen (OCGN), Rewalk Robotics (RWLK), Bionik Laboratories (BNKL), NanoVibronix (NAOV) and Avitar (AVTI). View all competitors. What other stocks do shareholders of Precision Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precision Therapeutics investors own include Inovio Pharmaceuticals (INO), Nokia Oyj (NOK), VBI Vaccines (VBIV), Achillion Pharmaceuticals (ACHN), Biocept (BIOC), NovaBay Pharmaceuticals (NBY), Neovasc (NVCN), Progenics Pharmaceuticals (PGNX), Vascular Biogenics (VBLT) and Achieve Life Sciences (ACHV). Who are Precision Therapeutics' key executives? Precision Therapeutics' management team includes the following people: Dr. Carl I. Schwartz, CEO & Director (Age 78)Mr. Robert L. Myers, CFO & Sec. (Age 64)Mr. David Orrin Johnson, Sr. VP of Operations - Skyline Medical Bus. Unit (Age 66)Mr. Kevin Hungerford, VP of Sales & Marketing What is Precision Therapeutics' stock symbol? Precision Therapeutics trades on the NASDAQ under the ticker symbol "POAI." Who are Precision Therapeutics' major shareholders? Precision Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Csenge Advisory Group (0.13%). Company insiders that own Precision Therapeutics stock include Carl I Schwartz and Richard L Gabriel. View institutional ownership trends for Precision Therapeutics. Which major investors are buying Precision Therapeutics stock? POAI stock was purchased by a variety of institutional investors in the last quarter, including Csenge Advisory Group. Company insiders that have bought Precision Therapeutics stock in the last two years include Carl I Schwartz, and Richard L Gabriel. View insider buying and selling activity for Precision Therapeutics. How do I buy shares of Precision Therapeutics? Shares of POAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Precision Therapeutics' stock price today? One share of POAI stock can currently be purchased for approximately $1.67. How big of a company is Precision Therapeutics? Precision Therapeutics has a market capitalization of $24.22 million and generates $1.41 million in revenue each year. Precision Therapeutics employs 24 workers across the globe. What is Precision Therapeutics' official website? The official website for Precision Therapeutics is www.precisiontherapeutics.com. How can I contact Precision Therapeutics? Precision Therapeutics' mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The medical instruments supplier can be reached via phone at 651-389-4800 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
